Zydus receives approval from DCGI to commence Phase III clinical trials with Pegylated Interferon alpha-2b in India


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ Zydus receives approval from DCGI to commence Phase III clinical trials with Pegylated Interferon alpha-2b in India
Zydus Cadila, had received an approval from the Drugs Controller General of India to start the Phase 3 clinical trial in COVID-19 patients with its biological therapy

Zydus Cadila, today announced that it had received an approval from the Drugs Controller General of India (DCGI) to start the Phase 3 clinical trial in COVID-19 patients with its biological therapy, Pegylated Interferon alpha-2b, ‘PegiHepTM’. The trials which will commence in December will be conducted on 250 patients across 20-25 centres in India. In the Phase II clinical trials study established the early safety, efficacy and tolerability of PegiHep TM and has indicated that Pegylated Interferon alpha-2b having statistical clinical beneficial impact on the patient suffering from moderate COVID 19 disease by reducing their viral load helping in better disease management such as reduced duration of oxygen support. Moreover, a single dose therapy will improve compliance and also make it highly affordable for patients. Pegylated Interferon alpha-2b, ‘PegiHepTM is an approved drug and is being re-purposed for the treatment of COVID-19.

Speaking on the development, Dr Sharvil Patel, Managing Director, Cadila Healthcare Ltd., said, “We are encouraged by the results of Phase II study of Pegylated Interferon alpha 2-b which has shown the potential to reduce virus titres when given earlier in the disease. Our efforts are to look at possible treatment options to fight COVID-19 which are safe, can be administered easily and also reduce the disease burden.”

In the Phase 2 clinical trial which was open-label, randomized, comparator controlled study, involving 40 adult patients with moderate COVID-19 disease, 95% subjects in the test arm who received a single dose of PegiHepTM along with the Standard Of Care (SOC), became virus free as assessed by RT-PCR on day 14 and showed a statistically significant clinical improvement over the patients in the reference arm, who received only the standard of care and where only 68% patients showed an improvement in clinical symptoms and became RT-PCR negative.

In the test arm 16 subjects were RT-PCR negative as early as day 7 of treatment which was an improvement over the reference arm. Clinical improvement was assessed using a seven point ordinal scale where the patients were assessed on multiple criteria such as requirement and duration of hospitalization, ventilation, supplemental oxygen etc.

Zydus Cadila is also conducting a similar Phase 2 trial in Mexico. The Company is also working with the USFDA to open an Investigational New Drug (IND) application for Pegylated Interferon alpha-2b in order to initiate appropriate clinical trials in US.

Pegylated Interferon alpha-2b is not a new therapy. The product was first approved internationally in 2001 and is also included in WHO’s Essential Medicines List. Zydus Cadila’s Pegylated Interferon alpha-2b, PegiHepTM, was originally approved for Hepatitis C and was launched in the Indian market in 2011. Since then safe and efficacious drug use for this product has been demonstrated in thousands of patients. Given that type I interferons including Interferon alpha have been implicated as crucial in the protection against SARS-CoV-2 in the recent publications in the leading journal Science (Hadjadj et al, Bastard et al and Zhang et al), the findings in Zydus Cadila’s Phase 2 study are not surprising. In this study, a single dose of PegiHep at 1 mcg/kg body weight was tested to find out whether the drug could be repurposed for treating moderate COVID-19 patients. In 19 out of 20 patients, a single 1 mcg/kg dose of the drug demonstrated viral clearance as assessed by RT-PCR and a significant improvement in clinical symptoms.

Tags : #ZydusCadila #LatestNewsonZydusCadila4thDec #LatestPharmaNews4thDec #LatestNewsonCOVIDTreatment4thDec #LatestDCGIApproval4thDec #Mexico #USFDA #WHO

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Hypertension in India: A Silent EpidemicMay 16, 2025
Know Your Blood Pressure & Keep It Under CheckMay 16, 2025
SBI Securities Contributed ₹49 Lakh to Enhance Eye Care Services in Odisha and West Bengal.May 16, 2025
7 Must Have Apps to Help You Break Free and Redefine Your Daily RoutineMay 16, 2025
Çelebi Aviation India Refutes False Allegations; Reaffirms Its Long-standing Commitment to India’s Aviation SectorMay 16, 2025
The Belly Bulge That Predicts the Future: What Every Parent Must KnowMay 16, 2025
Your Brain is Shrinking And Your Chair Might Be to BlameMay 16, 2025
Dengue on the Rise in India: A Wake-Up CallMay 15, 2025
Mumbai to Host Inter Passenger Terminal Show 2025 (IPTS 2025) May 15, 2025
Sharda Care Healthcity Saves 4-Year-Old Girl from Limb Amputation After Severe, Neglected InjuryMay 15, 2025
Indian students at Universities of Birmingham and Glasgow to get competitive advantage through exclusive careers supportMay 15, 2025
SIMS Hospital Performs South India’s First Combined Beating Heart Four Vessel Bypass and Pacemaker Implantation on 92-Year-Old DoctorMay 15, 2025
CoinDCX eyes over 30% of its revenue from the MENA region May 15, 2025
SBI Card Partners Apollo HealthCo; Introduces Apollo SBI Card SELECT CardMay 15, 2025
Top 5 E-Commerce Platforms in India for Your Every NeedMay 15, 2025
A for Accountability and Audit for TB deaths is missing in #EndTB responseMay 15, 2025
Inside India Inc’s Emotional Struggle: 84% of Employees Report Low Mood, Says HCL HealthcareMay 15, 2025
Early Signs of Alzheimer’s: What Doctors MissMay 15, 2025
Case based approach to Chronic Back Pain:May 15, 2025
Sensodyne’s latest campaign, addresses tooth sensitivity through real voicesMay 14, 2025